Nature Biotechnology
- 24, 922 - 926 (2006)
doi:10.1038/nbt0806-922
A change in the market—investing in diagnosticsKeith Batchelder & Peter Miller
Keith Batchelder and Peter Miller are at Genomic Healthcare Strategies, 22 Ninth Street, Charlestown, Massachusetts 02129, USA. peterm@genomichealthcarestrategies.com
Low margins, tricky reimbursement issues and the difficulty of market penetration have traditionally made diagnostics unattractive to investors. However, with changes to healthcare economics, regulation and the adoption of companion diagnostic tests that are predictive for drug response, that may be about to change.
|
